NexLife Expands Flat-Rate Compounded GLP-1 Program With Microdose and Sublingual Protocols

NexLife, a physician-led telehealth platform, announced expanded compounded GLP-1 programs with flat-rate pricing that remains constant across all dose levels, ranging from $119-$169 monthly depending on medication and plan length. The service includes $377 in bundled nutrition, coaching, and provider support at no additional cost, independent batch testing, and expedited delivery.

08/31/2026, 8:32 PM • GlobeNewswire

3 Things That Matter Most for Eli Lilly Now

Eli Lilly faces three key challenges despite its GLP-1 drug success: over-reliance on weight-loss medications (nearly two-thirds of revenue), inevitable growth slowdown as the market matures, and execution risk from acquisitions into new treatment areas. While the company's diversification strategy is prudent, investors should monitor these factors as the GLP-1 story may eventually lose momentum.

08/29/2026, 8:15 PM • The Motley Fool

Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?

Novo Nordisk, which pioneered GLP-1 weight-loss drugs but lost market leadership to Eli Lilly, is attempting a comeback through product innovation. The company has launched a pill version of Wegovy and partnered with Vivani Medical to develop an implant that could deliver the drug once or twice yearly, potentially revolutionizing convenience in the GLP-1 market. While Eli Lilly maintains a stronger market position and higher valuation, Novo Nordisk's continued innovation could help it regain competitive ground.

08/29/2026, 7:15 PM • The Motley Fool

AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

The article compares AbbVie and Eli Lilly as pharmaceutical investment options for 2026. AbbVie focuses on immunology and neuroscience with revenue of $61.2B and faces patent expiration risks, while Eli Lilly is experiencing explosive 45% revenue growth driven by its GLP-1 drugs (Mounjaro and Zepbound) with projected 2026 revenue of $85.2B. Despite Eli Lilly's higher valuation, the article recommends it for long-term investors due to the sustained demand and lifecycle nature of its metabolic therapies.

08/29/2026, 3:15 PM • The Motley Fool

Which Healthcare ETF Offers the Better Growth Outlook: VanEck Biotech or Invesco Pharmaceuticals?

The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with a lower 0.35% expense ratio and concentrated biotech focus, versus Invesco Pharmaceuticals ETF (PJP) with higher dividend yield and broader pharma exposure. Despite PJP's superior 5-year performance and lower volatility, the article concludes BBH is the better buy based on recent outperformance, though both funds offer targeted healthcare sector exposure with different risk-return profiles.

08/28/2026, 11:31 AM • The Motley Fool

Breast Cancer Therapeutics Market Size to Reach USD 95.14 Billion at a CAGR of 9.20% from 2035 – SNS Insider

The global breast cancer therapeutics market is projected to grow from USD 39.46 billion in 2025 to USD 95.14 billion by 2035, with a CAGR of 9.20%. Growth is driven by increased adoption of targeted therapies, CDK4/6 inhibitors, immunotherapy, and antibody-drug conjugates. North America leads with 38.61% market share, while Asia Pacific shows the fastest growth. Targeted therapy dominates with 64.85% share, while immunotherapy is the fastest-growing segment at 14.25% CAGR.

08/28/2026, 9:00 AM • GlobeNewswire

Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?

Revolution Medicines received rapid FDA approval for Rasonque, a novel pancreatic cancer treatment using a RAS inhibitor mechanism. The drug demonstrated strong Phase 3 trial results and analysts project peak annual sales of $11.5 billion. The stock has surged 178% year-to-date, with potential for further expansion into other cancer indications affecting 30% of solid tumors.

08/28/2026, 7:07 AM • The Motley Fool

2 Stocks That Could Capitalize on the GLP-1 Boom

The article highlights CVS Health and Roche as two stocks positioned to benefit from the growing GLP-1 drug market. CVS is leveraging its pharmacy network and low-cost telemedicine services to improve patient access to GLP-1 medications, while Roche is developing promising weight-loss drugs including CT-388, a dual GLP-1/GIP agonist showing strong clinical results. Both companies offer diversified business models beyond GLP-1 to mitigate risks.

08/25/2026, 3:18 PM • The Motley Fool

For Investors in Their 30s, Here's 1 Glorious Growth ETF to Buy Hand Over Fist and Hold Forever

The Vanguard Morningstar Mega Cap Growth ETF (MGK) is recommended for investors in their 30s seeking long-term growth. With 72% exposure to technology stocks and top holdings in Nvidia, Apple, and Microsoft, the ETF has delivered 13.6% compound annual returns since 2007, outperforming the S&P 500's 10.9%. A $30,000 investment could yield approximately $700,000 more at retirement compared to conservative alternatives, though diversification is advised.

08/25/2026, 7:30 AM • The Motley Fool

3 Growth Stocks That Could Skyrocket in the Second Half of 2026

The article highlights three growth stocks positioned for strong performance in the second half of 2026: Arista Networks benefits from accelerating data center spending with record $3B quarterly revenue and 45% operating margins; Micron is capitalizing on AI-driven demand for high bandwidth memory with 346% YoY revenue growth and strong guidance; and Eli Lilly is experiencing explosive growth from its GLP-1 drugs Mounjaro and Zepbound, raising full-year revenue guidance to $85-87B.

08/23/2026, 8:12 PM • The Motley Fool

Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger

Eli Lilly's weight-loss pill Foundayo received U.K. approval, marking Europe's first GLP-1 oral medication authorization. The drug offers advantages over competitor Novo Nordisk's Wegovy with no food restrictions. The global obesity drug market is projected to grow from $66 billion in 2025 to $92-200 billion by 2027, presenting significant growth opportunities for multiple manufacturers.

08/14/2026, 10:30 AM • The Motley Fool

Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?

Fidelity MSCI Health Care Index ETF (FHLC) and iShares U.S. Pharmaceuticals ETF (IHE) offer different approaches to healthcare investing. FHLC provides broad diversification across 338 healthcare holdings with a lower 0.08% expense ratio, while IHE focuses on 56 pharmaceutical stocks with higher concentration risk but delivered 60% one-year returns. The analysis recommends FHLC for its superior diversification and lower costs, despite IHE's recent outperformance.

08/14/2026, 7:15 AM • The Motley Fool

Simplify's PINK or iShares' IYH: Which Healthcare ETF Should Long-Term Investors Choose Right Now?

Simplify Health Care ETF (PINK) has delivered superior 1-year returns of 42% versus iShares U.S. Healthcare ETF's (IYH) 31.4%, driven by active management focused on healthcare innovation and a charitable mission donating profits to cancer research. However, IYH offers lower costs (0.38% vs 0.51% expense ratio), higher dividend yield (1.1% vs 0.6%), and a proven 25+ year track record, making it the more suitable choice for most long-term conservative investors despite PINK's recent outperformance.

08/13/2026, 3:34 PM • The Motley Fool

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

Eli Lilly and Viking Therapeutics are competing in the rapidly growing GLP-1 drug market. Eli Lilly leads with approved products like tirzepatide generating strong revenue ($9.9B for Mounjaro, $4.9B for Zepbound in Q2), while Viking Therapeutics is a clinical-stage biotech with promising VK2735 candidate showing strong phase 2 results. The article recommends Eli Lilly as the safer choice due to its established portfolio and limited downside risk, though Viking Therapeutics offers higher upside potential if its phase 3 trials succeed.

08/08/2026, 3:30 PM • The Motley Fool

iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond?

The article compares two healthcare-focused ETFs: iShares Global Healthcare ETF (IXJ) and State Street SPDR S&P Biotech ETF (XBI). XBI delivered superior 1-year returns of 80.2% with small-cap biotech focus but carries higher volatility (54% max drawdown). IXJ offers more stability with lower volatility, higher dividend yield (1.4%), and international diversification across large-cap pharmaceutical and healthcare companies. The analysis recommends XBI for long-term investors prioritizing performance despite greater risk.

08/08/2026, 12:02 PM • The Motley Fool